I don't feel that ambition and risk is a bad thing. Elon Musk is crazier than you give him credit for. He started Neuralink, which is even more of a moonshot bi

I don't feel that ambition and risk is a bad thing. Elon Musk is crazier than you give him credit for. He started Neuralink, which is even more of a moonshot biotech company. I think that starting a new car/rocket company was riskier, back in 2003, for economic and political reasons. However, I agree that Juvenescence has too much hype and not enough detail. Musk talks big but gives detailed arguments about why he can succeed. Here they seem to just want to get their name out. I'm particularly concerned that Mellon is running a biotech VC fund, juvenescence.life, which incentives PR over substance. All I've read so far is that they want to apply ML to improve the drug pipeline and discover better drugs. It's not a new idea. There is existing research on using neural networks to predict drug effects, and more broadly many are working on high throughout screening for drug candidates, fully robotic wet labs, etc. But aspects of drug discovery are poorly suited for AI: it's a complex, heterogeneous process requiring logical reasoning and modeling on top of immense structured domain knowledge. The burden is on Juvenescence to make a convincing pitch.